Generic Product News
92 PharmacyTimes.com December 2015
®
MONTELUKAST SODIUM
CHEWABLE TABLETS
Marketed by: Camber Pharmaceuticals
Compare to: Singulair (Merck)
Indication: Camber Pharmaceuticals
announced the launch of Montelukast
Sodium Chewable Tablets in 4- and
5-mg tablet strengths. The drug is
indicated to treat chronic asthma in
adults and in children 1 year or older.
The product will be available in 30-
and 90-count bottles.
Dosage Form: Chewable tablets: 4 and
5 mg
For More Information:
www.camberpharma.com
MEMANTINE HYDROCHLORIDE
TABLETS USP, 5 MG AND 10 MG
Marketed by: Aurobindo Pharma
Limited
Compare to: Namenda (Forest
Laboratories, Inc)
Indication: Aurobindo Pharma
announced FDA approval of its
Memantine Hydrochloride Tablets USP
in 5- and 10-mg dosage strengths. The
product is indicated to treat moderate
to severe dementia of the Alzheimer's
type.
Dosage Form: Tablets: 5 and 10 mg
For More Information:
www.aurobindousa.com
LEVOLEUCOVORIN CALCIUM
INJECTION
Marketed by: Mylan
Compare to: Fusilev (Spectrum
Pharmaceuticals)
Indication: Mylan has launched
Levoleucovorin Calcium Injection,
the generic equivalent to Spectrum
Pharmaceuticals' Fusilev, in 10 mg
(base)/mL, 175 mg (base)/17.5 mL, and
250 mg (base)/25 mL single-use vials.
The product is indicated for rescue use
after high-dose methotrexate therapy
in osteosarcoma. It can also be used
to lower toxicity and counteract the
effects of impaired methotrexate
elimination and of inadvertent over-
dosage of folic acid antagonists.
Dosage Form: Single-use vials: 10 mg
(base)/mL, 175 mg (base)/17.5 mL, and
250 mg (base)/25 mL
For More Information:
www.mylan.com
Dutasteride
Capsules
NDC 65862-652-60
Rx only 60 Tablets
PHARMACIST: Dispense the patient
information leaflet provided separately
to each patient.
Memantine Hydrochloride
Tablets USP 5 mg
Marketed by: Teva Pharmaceuticals USA
Compare to: Avodart (GlaxoSmithKline)
Indication: Teva Generics announced the
launch of Dutasteride Capsules, the thera-
peutic equivalent to GlaxoSmithKline's
Avodart, in a 0.5-mg dosage strength. The
product is indicated to treat symptomatic
benign prostatic hyperplasia (BPH) in men
with an enlarged prostate to reduce the
risk of acute urinary retention, improve
symptoms, and reduce the possibility of
needing BPH-related surgery. The product
is not approved to prevent prostate cancer.
Dosage Form: Capsules: 0.5 mg
For More Information:
www.tevagenerics.com